EN DE

Skin Laboratory Public Company (SKIN) Fair Value & Analysis

Consumer Defensive · TH · Market cap 130M THB

SL Skin Laboratory Public Company SKIN · BK
Price0.8900 THB
Fair Value0.6100 THB
Upside-31.5%
Quality59/100
Watch Skin Laboratory Public Company for free, get notified when fair value or trend changes. Watch for free
Weak Growth
Loss-making · -4.7% net margin
generates free cash flow
Mixed vs. peers (4/9)
Narrow moat 19/100
Evidence: High Range 0.4600 THB – 0.7600 THB Share as image

Fair value as of: Jul 15, 2026

From 22 valuation models · updated 27 days ago

Fair value updated Jul 15, 2026, revised from 1.02 THB to 0.6100 THB (−40.2%) since Jun 24, 2026. Share price +1.1% over the past month.

A solid business, but screening 31% overvalued on our models.

What matters now

  • The price sits above even our optimistic bull case (0.7600 THB). The favourable scenario is already priced in.
  • Solid but not exceptional quality (59/100) and above fair value, neither a clear bargain nor a standout compounder.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (11 months)

3.62 THB 0.7800 THB Fair Value 0.6100 THB Sep 2025 Aug 2026

White line = price, green steps = our fair value per fiscal year. As of Jul 15, 2026.

How to read this chart

11‑month range 0.7800 THB – 3.62 THB · fair‑value band 0.4600 THB – 0.7600 THB · the 0.8900 THB price screens above the 0.6100 THB fair value. As of Jul 15, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Skin Laboratory Public Company (SKIN) currently trades at 0.8900 THB, while our model-based Fair Value estimate is 0.6100 THB, implying the stock looks roughly 31.5% overvalued today. The Quality Score stands at 59/100 (solid quality), in the Consumer Defensive sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).

Over the trailing twelve months, Skin Laboratory Public Company generated revenue of 167M THB at a net margin of -4.7%. Revenue declined 24.8% year over year. It earns a return on equity of -10.0%. Fundamentals as of Jul 15, 2026

Our scenario range runs from 0.4600 THB (bear case) to 0.7600 THB (bull case); at 0.8900 THB, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 79% below its 52-week high and 11% above its 52-week low, currently below its 200-day average. For context, the median of 10 Consumer Defensive peers we cover trades at -26% fair-value upside, at -31%, SKIN screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model Bear Bear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull Bull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
Residual Income 0.4700 THB 0.4500 THB 0.3600 THB 76
Growth DCF 1.14 THB 1.30 THB 1.52 THB 72
Growth-Adj P/E 0.3400 THB 0.4800 THB 0.6300 THB 68
All 22 models by family
DCF Models
FCF DCF 1.13 THB 1.29 THB 1.55 THB 38
Owner Earnings 0.8100 THB 0.8900 THB 1.02 THB 31
5Y Revenue Exit 0.9700 THB 1.12 THB 1.33 THB 39
5Y EBITDA Exit 1.03 THB 1.21 THB 1.46 THB 41
5Y P/E Exit 1.02 THB 1.19 THB 1.40 THB 38
10Y Revenue Exit 1.04 THB 1.14 THB 1.25 THB 36
10Y EBITDA Exit 1.07 THB 1.19 THB 1.31 THB 37
10Y P/E Exit 1.07 THB 1.18 THB 1.28 THB 35
Earnings-Based
Graham-Dodd 0.2100 THB 0.2500 THB 0.2800 THB 54
EPV 0.7300 THB 0.7500 THB 0.7800 THB 59
Multiples
P/E Multiple 0.4800 THB 0.6400 THB 0.8000 THB 63
P/S Multiple 0.3900 THB 0.5200 THB 0.6500 THB 58
P/B Multiple 0.3900 THB 0.5200 THB 0.6500 THB 55
EV/EBIT 1.01 THB 1.18 THB 1.35 THB 53
EV/EBITDA 1.01 THB 1.18 THB 1.35 THB 54
EV/Revenue 0.8700 THB 1.02 THB 1.18 THB 43
Asset-Based
NCAV (Graham) 0.3500 THB 0.4700 THB 0.7000 THB 50
Growth DCF
Growth DCF 1.14 THB 1.30 THB 1.52 THB 72
Rev-Margin DCF 0.9700 THB 1.14 THB 1.35 THB 67
Economic Profit
Residual Income 0.4700 THB 0.4500 THB 0.3600 THB 76
ROIC Compounder 0.7300 THB 0.7600 THB 0.7900 THB 67
Growth Earnings
Growth-Adj P/E 0.3400 THB 0.4800 THB 0.6300 THB 68

Widest divergence: DCF Models (1.18 THB) versus Earnings-Based (0.2500 THB). Highest evidence: Residual Income (76).

Notify me when SKIN reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

Revenue (TTM) 167M THB
Revenue growth (YoY) -24.8%
Net margin -4.7%
Return on equity -10.0%
Free cash flow 12.5M THB FY2025
Operating margin -20.6%
More key figures
EPS (TTM) -0.0500 THB

Figures from reported company fundamentals · as of Jul 15, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 59/100

Of which business quality 66 · Market factors (momentum, volatility) 6

Profitability 57
Margins and returns on capital today
Quality Growth 5
Are margins and returns improving?
Cashflow 69
Earnings quality: real cash, not paper profit
Fin. Strength 100
Balance sheet, leverage, solvency risk
Investment 68
Disciplined investing over empire-building
Low Volatility 0
Calm price path (market factor)
Momentum 13
Price trend over the last 3–12 months (market factor)
52W Momentum 2
Distance to the 52-week high (market factor)
Net Issuance 82
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

Skin Laboratory Public Company Limited manufactures and distributes beauty products in Thailand and internationally. The company offers skincare products, beauty creams, cosmetics, and dietary supplements under the Skinsista and Dermie brand names. It sells its products through online channels and stores.

Full company description

Skin Laboratory Public Company Limited manufactures and distributes beauty products in Thailand and internationally. The company offers skincare products, beauty creams, cosmetics, and dietary supplements under the Skinsista and Dermie brand names. It sells its products through online channels and stores. The company was incorporated in 2013 and is headquartered in Nonthaburi, Thailand.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2022 – FY2025 · reported fiscal years

Skin Laboratory Public Company reported revenue of 177M THB in FY2025 versus 282M THB in FY2022, a compound −14.4%/yr. Reported net income was 4.4M THB in FY2025, compounding −25.8%/yr from FY2022.

Growth Quality 40/100
Revenue growth is weak, negative or inconsistent.
Latest Revenue (FY 2025)
177M THB
Latest YoY
−22.9%
Avg. growth/yr (3Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
−14.4%
Revenue −14.4%/yr
FY22 282M THB
FY23 272M THB
FY24 229M THB
FY25 177M THB
Net income −25.8%/yr
FY22 10.7M THB
FY23 16.7M THB
FY24 10.7M THB
FY25 4.4M THB

SKIN screens 31% overvalued. Compare with The Procter & Gamble Company →

Share or link this analysis
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "Skin Laboratory Public Company Fair Value". https://www.fairvalue-calculator.com/stock/SKIN

Peer Group

Household & Personal Products · 244 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 59 · Above median
Fair Value upside −32% · Below median
Return on assets 3% · Above median
Net margin (TTM) -5% · Bottom 25%
Operating margin (TTM) -21% · Bottom 25%
Revenue growth -25% · Bottom 25%

Valuation Multiples vs Household & Personal Products median · lower = cheaper

P/S (TTM) 0.02× · Cheaper than 75% of peers
P/FCF 0.3× · Cheaper than median

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Household & Personal Products stocks, each showing price versus our Fair Value estimate (as of Jul 15, 2026).

Stock Price Fair Value vs Fair Value
The Procter & Gamble Company PG $146.80 $108.16 -26%
Unilever PLC ULN 1,080 MXN 1,273 MXN +18%
Hindustan Unilever Limited HINDUNILVR ₹2,144 ₹1,000 -53%
Essity AB ESSITYA kr 279.00 kr 250.02 -10%
Godrej Consumer Products Limited GODREJCP ₹1,088 ₹367.64 -66%
Marico Limited MARICO ₹846.75 ₹233.05 -72%
APR Co 278470 375,000 KRW 151,222 KRW -60%
Dabur India Limited DABUR ₹429.45 ₹181.60 -58%
Kimberly-Clark de México, S. A. B. de C. V., KIMBERA 38.07 MXN 50.09 MXN +32%
PT Unilever Indonesia Tbk UNVR 1,730 IDR 1,934 IDR +12%

Compare Skin Laboratory Public Company with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Consumer Defensive stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is Skin Laboratory Public Company (SKIN) overvalued or undervalued?
As of Jul 15, 2026, our model estimates a fair value of 0.6100 THB versus a price of 0.8900 THB, about −31% (overvalued).
What is the fair value of SKIN?
Our model-based fair value for Skin Laboratory Public Company is 0.6100 THB (as of Jul 15, 2026), built from audited fundamentals. The current price is 0.8900 THB.
What is the quality score of SKIN?
Skin Laboratory Public Company has a Quality Score of 59/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of Skin Laboratory Public Company (SKIN)?
Skin Laboratory Public Company reported trailing-twelve-month revenue of about 167M THB (latest available figure, as of Jul 15, 2026).
What is the net profit margin of SKIN?
The net profit margin of Skin Laboratory Public Company is about -4.7%, meaning it is currently running at a net loss. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track Skin Laboratory Public Company and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.